Manipulation of the bacterial flora in inflammatory bowel disease.
In this chapter we summarize the clinical and experimental data which indicate that bacteria, especially from the endogenous microflora, play a role in the pathogenesis of Crohn's disease, ulcerative colitis and pouchitis. We review the clinical trials, focusing on randomized controlled trials which used antibiotics or probiotics to treat situations of IBD or prevent recurrence, and we discuss the future of this approach.
Marteau
Philippe
P
Gastroenterology Department, European Hospital Georges Pompidou, AP-HP & Paris V University, France.
Seksik
Philippe
P
Shanahan
Fergus
F
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004755:Enterobacteriaceae / Q000187:drug effects*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000382:microbiology* / Q000503:physiopathology; D009593:Nitroimidazoles / Q000627:therapeutic use*; D019449:Pouchitis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D019936:Probiotics / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D009593:Nitroimidazoles; D002939:Ciprofloxacin